Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 7/20 | 0.58 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.58 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.58 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.51 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.51 |
| ▸ | CD69 | Q07108 | 1/20 | 0.50 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.49 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.47 |
| ▸ | FGF1 | P05230 | 1/20 | 0.47 |
| ▸ | FGF2 | P09038 | 1/20 | 0.47 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17945670 | 1.00 | LGALS3 (0.58) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL21134603 | 1.00 | LGALS3 (0.58) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL17955020 | 1.00 | LGALS3 (0.58) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL17950825 | 1.00 | LGALS3 (0.58) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL7717434 | 0.97 | LGALS3 (0.62) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL7717439 | 0.97 | LGALS3 (0.62) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL18649615 | 0.93 | LGALS3 (0.52) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL18645639 | 0.93 | LGALS3 (0.52) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL16407357 | 0.92 | LGALS3 (0.64) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B | |
| SCHEMBL23613765 | 0.92 | LGALS3 (0.64) | LGALS3LGALS8LGALS4LGALS1LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3789766-A1 | NOVEL GLYCAN CONJUGATES AND METHODS OF USE THEREOF | Academia Sinica (TW) | 2021-03-10 | — | — | EP | disclosed |
| EP-3248005-B1 | NOVEL GLYCAN CONJUGATES AND METHODS OF USE THEREOF | ACADEMIA SINICA (TW) | 2020-12-09 | — | — | EP | disclosed |
| US-20200200758-A1 | CANCER MARKERS AND METHODS OF USE THEREOF | ACADEMIA SINICA (TW) | 2020-06-25 | — | — | US | disclosed |
| WO-2017100796-A1 | MODULATION OF GLOBOSERIES GLYCOSPHINGOLIPID SYNTHESIS AND CANCER BIOMARKERS | SINACA, Academia (TW) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200200758-A1 | CANCER MARKERS AND METHODS OF USE THEREOF | B3GAT3, ST6GAL1, B4GALT1 | LGALS3 32/4885LGALS8 76/4885LGALS4 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.